long intergenic non-protein coding RNA 2237Genealiases: []
Q-omics provides the consensus-scored LINC02237 profile across patient tissues and cancer cell-line models. LINC02237 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, LINC02237 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, LINC02237 RNA expression shows 10,892 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, and ACC as cancer lineages where LINC02237 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02237 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02237 survival associations across molecular data types. LINC02237 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02237 RNA expression–survival associations across cancer types. High LINC02237 expression shows unfavorable associations in CESC, UCEC, SKCM and ACC, but favorable associations in THCA and LGG. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for LINC02237 RNA expression.
This table summarizes LINC02237 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02237. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02237 shows lower tumor expression in THCA, BRCA, COAD, READ, STAD and BLCA. The THCA box plot shows higher LINC02237 RNA expression in normal versus tumor tissue (log2 FC = −0.332, t-test p < 0.001).
This table shows molecular features associated with LINC02237 in patient tissues and cancer cell lines. In patient samples, LINC02237 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
